Seelos Therapeutics, Inc. (SEEL) News
Filter SEEL News Items
SEEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SEEL News Highlights
- SEEL's 30 day story count now stands at 2.
- Over the past 2 days, the trend for SEEL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RARE are the most mentioned tickers in articles about SEEL.
Latest SEEL News From Around the Web
Below are the latest news stories about SEELOS THERAPEUTICS INC that investors may wish to consider to help them evaluate SEEL as an investment opportunity.
Seelos Therapeutics, Inc. Releases Letter to its StockholdersSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released a letter to its stockholders from Raj Mehra, Ph.D., Chairman and Chief Executive Officer of Seelos, the text of which is copied below. |
11 Most Promising Psychedelic Stocks According to Hedge FundsIn this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […] |
Insider Spends US$100k Buying More Shares In Seelos TherapeuticsInvestors who take an interest in Seelos Therapeutics, Inc. ( NASDAQ:SEEL ) should definitely note that the Chief... |
Insider Buying: CFO Michael Golembiewski Acquires 83,000 Shares of Seelos Therapeutics Inc (SEEL)In the realm of stock market movements, insider trading can provide valuable insights into a company's health and future prospects. |
Seelos Therapeutics Announces Closing of Public OfferingSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 1,781,934 shares of its common stock, pre-funded warrants to purchase up to 2,422,612 shares of its common stock and accompanying common warrants to purchase up to 4,204,546 shares of its common stock. Each share of comm |
Why Are Stocks Up Today?Stocks are up today as investors react to the latest comments from members of the Federal Reserve and an increased Consumer Confidence Index. |
Why Is Leslie’s (LESL) Stock Down 24% Today?Leslie's stock is falling hard on Wednesday as investors in LESL react to it missing EPS estimates in Q4 and posting weak 2024 guidance. |
Why Is Seelos Therapeutics (SEEL) Stock Down 42% Today?Seelos Therapeutics stock is falling on Wednesday after the company announced and priced a public offering for shares of SEEL. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning! |
Seelos Therapeutics Announces Pricing of $5.55 Million Public OfferingSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has priced its underwritten public offering of 1,781,934 shares of its common stock, pre-funded warrants to purchase up to 2,422,612 shares of its common stock and accompanying common warrants to purchase up to 4,204,546 shares of its common stock. Each share of common stock and acco |